Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Attruby cruises toward blockbuster land as BridgeBio CEO spots ‘stabilizer-first’ ATTR market
As Alnylam’s Amvuttra sales disappointed, revenue from BridgeBio’s rival transthyretin amyloidosis (ATTR) drug Attruby came in above analysts’ expectations. | Despite their divergent second-quarter performance against consensus estimates, BridgeBio and Alnylam are now targeting the same population—first-line ATTR-CM patients—as the silencer-vs-stabilizer debate drags on.
TL;DRAI
Attruby beat consensus with $222M Q2 US sales, tracking $1B annual revenue, while rival Amvuttra disappointed. Wainua trial failure confirms stabilizer-first ATTR-CM market dominance, positioning BridgeBio for $4B+ peak sales.
662 words~3 min read
